AbbVie Enhances Shareholder Value with Quarterly Dividend Announcement

AbbVie Announces $1.73 Quarterly Dividend

The board of directors of AbbVie Inc. (NYSE: ABBV) has officially declared a quarterly cash dividend amounting to $1.73 per share. This noteworthy announcement was made on September 10, 2026, and the cash dividend is set to be payable on November 16, 2026. Stockholders who are on record by the closing of business on October 15, 2026, will be eligible to receive this dividend.

Since its establishment in 2013, AbbVie has demonstrated impressive growth in its dividend distribution, having increased it by over 330% since its inception. This remarkable growth highlights AbbVie's strong financial fundamentals and commitment to returning value to its shareholders.

AbbVie is recognized as a member of the S&P Dividend Aristocrats Index, a prestigious list that includes companies that have successfully raised their dividends for at least 25 consecutive years. This accolade reflects the company's historical performance and its ongoing strategy to provide consistent financial returns to investors.

In the competitive pharmaceutical industry, AbbVie’s dividend strategy underscores its resilience and ability to maintain profitability even in challenging market conditions. The company’s commitment to balancing both sustainable growth and shareholder rewards is evident as it continues to invest in innovative solutions that address significant health issues across various therapeutic areas, including immunology, oncology, and neuroscience.

AbbVie's Mission and Vision

AbbVie’s vision extends beyond merely providing dividends. The company is dedicated to innovating medicines and solutions that cater to pressing health challenges today and possibly lay groundwork for addressing future medical concerns. Their mission is to create a notable impact on people’s lives through advancements in critical therapeutic areas.

With a vast product portfolio, including offerings in the Allergan Aesthetics segment, AbbVie stands at the forefront of the healthcare industry, making strides towards delivering innovative healthcare solutions. Investors are encouraged to follow AbbVie as it continues its journey, providing ongoing updates on its corporate developments and product advancements.

For further updates, information about AbbVie, and its product offerings, visit their official website at www.abbvie.com. Additionally, you can stay connected with AbbVie via social media platforms, including LinkedIn, Facebook, Instagram, X, and YouTube, as they share news, insights, and corporate information.

Conclusion

In summary, AbbVie’s announcement of a quarterly dividend exemplifies its strong financial health and commitment to enhancing shareholder value. As the company continues to innovate and expand its portfolio in the ever-evolving pharmaceutical landscape, investors remain optimistic about the positive trajectory of AbbVie Inc.

For any inquiries or further information, investors can reach out to AbbVie’s investor relations team: Catherine Langel at (708) 508-3524 or Liz Shea at (847) 935-2211.